Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 4/2016

16.11.2015 | Original Article

Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population

verfasst von: Birgul Onec, Harika Okutan, Murat Albayrak, Esra Sarıbacak Can, Vedat Aslan, Ozge Soyer Kosemehmetoglu, Basak Unver Koluman

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Multiple myeloma (MM) is a disease of the geriatric population with a median age at diagnosis of 69 years but most clinicians consider performance status and comorbidities rather than chronological age in determining prognosis and treatment. The purpose of this study was to assess whether and which comorbidity indices predict survival in a real life population of MM. We calculated Charlson Comorbidity Index (CCI), age combined Charlson index (CCI-age), Hematopoietic cell transplantation-specific comorbidity index (HCT-SCI) and Freiburger comorbidity index (FCI) retrospectively for 66 MM patients and compared their impact on treatment responses and overall survival (OS). Treatment response was significantly worse in groups with high CCI, CCI-age, HCT-SCI scales (p < 0.05), but FCI’s effect on treatment response was not significant. However, while no significant relationship was determined between other comorbidity indices with OS, it was related only with FCI–CI (p = 0.006). FCI, developed in this patient group, was the only prognostic index with a significant effect on OS in the evaluation of comorbidities in MM patients with different scores, but its relationship to treatment responses was not significant contrary to other indices. While this small patient group gave us hope regarding the use of FCI in practice, multi-center studies are still required.
Literatur
1.
Zurück zum Zitat Munshi NC, Jagannath S (2013) Plasma cell neoplasms. In: Hoffman R, Benz EJ, Silberstein L, Heslop H, Weitz J, Anastasi J (eds) Hematology, basic principles and practice, 6th edn. Saunders, Philadelphia, pp 1303–1337 Munshi NC, Jagannath S (2013) Plasma cell neoplasms. In: Hoffman R, Benz EJ, Silberstein L, Heslop H, Weitz J, Anastasi J (eds) Hematology, basic principles and practice, 6th edn. Saunders, Philadelphia, pp 1303–1337
2.
Zurück zum Zitat Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M et al (2012) Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 12(6):423–432CrossRefPubMed Offidani M, Corvatta L, Polloni C, Centurioni R, Visani G, Brunori M et al (2012) Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry. Clin Lymphoma Myeloma Leuk 12(6):423–432CrossRefPubMed
3.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
4.
Zurück zum Zitat Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMed Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47(11):1245–1251CrossRefPubMed
5.
Zurück zum Zitat Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919CrossRefPubMedPubMedCentral Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8):2912–2919CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R et al (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1(9):e35CrossRefPubMedPubMedCentral Kleber M, Ihorst G, Terhorst M, Koch B, Deschler B, Wasch R et al (2011) Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score. Blood Cancer J 1(9):e35CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT et al (2012) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 95(1):64–70CrossRefPubMed Kaya H, Peressini B, Jawed I, Martincic D, Elaimy AL, Lamoreaux WT et al (2012) Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int J Hematol 95(1):64–70CrossRefPubMed
8.
Zurück zum Zitat Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420CrossRefPubMed Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420CrossRefPubMed
9.
Zurück zum Zitat Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al (2013) Mayo clinic. management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc Mayo Clin 88(4):360–376CrossRefPubMed Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al (2013) Mayo clinic. management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc Mayo Clin 88(4):360–376CrossRefPubMed
10.
Zurück zum Zitat Durie BG, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55(3):364–372PubMed Durie BG, Salmon SE, Moon TE (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood 55(3):364–372PubMed
11.
Zurück zum Zitat Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519–4529CrossRefPubMed Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Blade J, Mateos MV et al (2011) Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 118(17):4519–4529CrossRefPubMed
12.
Zurück zum Zitat Wang R, Gross CP, Halene S, Ma X (2009) Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33(12):1594–1598CrossRefPubMedPubMedCentral Wang R, Gross CP, Halene S, Ma X (2009) Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res 33(12):1594–1598CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090–1098CrossRefPubMed Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E et al (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106(5):1090–1098CrossRefPubMed
14.
Zurück zum Zitat Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R et al (2013) Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 13(5):541–551CrossRefPubMed Kleber M, Ihorst G, Gross B, Koch B, Reinhardt H, Wasch R et al (2013) Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome. Clin Lymphoma Myeloma Leuk 13(5):541–551CrossRefPubMed
15.
Zurück zum Zitat Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7–8):387–404CrossRefPubMed Kaplan MH, Feinstein AR (1974) The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 27(7–8):387–404CrossRefPubMed
16.
Zurück zum Zitat Kleber M, Ihorst G, Udi J, Koch B, Wasch R, Engelhardt M (2012) Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk 12(1):38–48CrossRefPubMed Kleber M, Ihorst G, Udi J, Koch B, Wasch R, Engelhardt M (2012) Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. Clin Lymphoma Myeloma Leuk 12(1):38–48CrossRefPubMed
Metadaten
Titel
Comparative Evaluation of Common Comorbidity Scores and Freiburger Comorbidity Index as Prognostic Variables in a Real Life Multiple Myeloma Population
verfasst von
Birgul Onec
Harika Okutan
Murat Albayrak
Esra Sarıbacak Can
Vedat Aslan
Ozge Soyer Kosemehmetoglu
Basak Unver Koluman
Publikationsdatum
16.11.2015
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 4/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-015-0618-y

Weitere Artikel der Ausgabe 4/2016

Indian Journal of Hematology and Blood Transfusion 4/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.